ALGS (Aligos Therapeutics) Total Current Assets: $59.63 Mil (As of Mar. 2026)

What is Aligos Therapeutics Total Current Assets?

Aligos Therapeutics ALGS -2.22% 37 Total Current Assets is $59.63 Mil as of Mar. 2026. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Aligos Therapeutics's total current assets for the quarter that ended in Mar. 2026 was $59.63 Mil.

Aligos Therapeutics (NAS:ALGS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Aligos Therapeutics's Liquidation Value for the quarter that ended in Mar. 2026 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	54.909	-	32.769	+	0.75 * 0	+	0.5 * 0
=	22.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Total Current Assets Related Terms

Aligos Therapeutics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Total Current Assets can be seen below:

Aligos Therapeutics Total Current Assets Chart

Aligos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Current Assets

Get a 7-Day Free Trial

204.42

133.55

141.08

62.14

82.86

Aligos Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Current Assets	Get a 7-Day Free Trial															143.21	127.94	103.44	82.86	59.63

37GF Score

Aligos Therapeutics Inc ALGS

Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aligos Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Aligos Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	77.844	+	0	+	0	+	5.018
	=	82.86

Aligos Therapeutics's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	54.909	+	0	+	0	+	4.72
	=	59.63

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →

What does a Total Current Assets of $59.63 Mil mean?

Aligos Therapeutics (ALGS) has a Total Current Assets of $59.63 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Aligos Therapeutics and its competitors.

Is Aligos Therapeutics' Total Current Assets too high?

Aligos Therapeutics' current Total Current Assets is $59.63 Mil. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aligos Therapeutics' Total Current Assets compare to SNTI and NTRB?

Aligos Therapeutics' Total Current Assets of $59.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Current Assets for a Biotechnology company?

A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Current Assets mean?

A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Aligos Therapeutics and its competitors. Aligos Therapeutics's current Total Current Assets is $59.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aligos Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current Total Current Assets is $59.63 Mil. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Current Assets calculated?

Total Current Assets is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Total Current Assets is $59.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

Total Current Assets: $59.63 Mil
GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SNTI NTRB CRVO DARE INMB ATNM NNVC GRCE LSTA SGMO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 5WK0:Germany

Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080

Website https://www.aligos.com

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

37GF Score

Get the complete analysis for ALGS

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63

Price

$2.78

GF Value

View ALGS Analysis

See Total Current Assets data for all stocks →